Compare FAF & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FAF | PCVX |
|---|---|---|
| Founded | 1889 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 6.1B |
| IPO Year | N/A | 2020 |
| Metric | FAF | PCVX |
|---|---|---|
| Price | $60.63 | $45.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $75.75 | ★ $105.00 |
| AVG Volume (30 Days) | 690.1K | ★ 1.2M |
| Earning Date | 02-11-2026 | 02-24-2026 |
| Dividend Yield | ★ 3.62% | N/A |
| EPS Growth | ★ 428.61 | N/A |
| EPS | ★ 4.65 | N/A |
| Revenue | ★ $7,087,600,000.00 | N/A |
| Revenue This Year | $19.19 | N/A |
| Revenue Next Year | $7.53 | N/A |
| P/E Ratio | $13.09 | ★ N/A |
| Revenue Growth | ★ 20.70 | N/A |
| 52 Week Low | $53.09 | $27.66 |
| 52 Week High | $68.64 | $93.77 |
| Indicator | FAF | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 40.53 | 47.76 |
| Support Level | $58.50 | $44.57 |
| Resistance Level | $63.07 | $47.72 |
| Average True Range (ATR) | 1.52 | 1.76 |
| MACD | -0.12 | -0.10 |
| Stochastic Oscillator | 43.21 | 28.40 |
First American Financial Corp is a financial services business providing insurance through segments: Title insurance and related services segment include real estate insurance, property closing services, third-party handling of real estate funds (escrow), risk mitigation, real estate data products, and related real estate transaction services; The home warranty segment provides residential service contracts that cover residential systems, such as heating and air conditioning systems, and certain appliances against failures that occur as the result of normal usage during the coverage period; and The corporate segment includes investments in venture-stage companies, certain financing facilities and corporate services supporting the company's business operations.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.